Nintedanib is reported to have a senolytic effect through the inhibition of STAT3. Research on nintedanib's effects has also explored its potential in treating various conditions, including radiation-induced lung injury, pulmonary fibrosis, and dermatitis. The drug's impact on fibroblasts, particularly in lung adenocarcinoma patients, has also been studied, although its broader effects on senescent cells and aging patterns are still being investigated.